Expert Interview
Discussing the recent Phase 1B data from Celldex on Barzolvolimab (CDX-0159) in treating Spontaneous Urticaria
Ticker(s): CLDXInstitution: Children's Hospital Colorado
- Assistant Professor at the University of Colorado School of Medicine and Fellowship Director of Allergy and Immunology.
- Treats 12 patients with HAE, over 50 patients with spontaneous urticaria and 150 total patients with EoE.
- Clinical interests include food allergy, eosinophilic esophagitis, asthma, allergic rhinitis, eczema, drug allergy and urticaria.
Roughly how many patients with urticaria do you currently manage?
What were your initial impressions of the recent Phase 1B data on CDX-1059?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for CDX-0159?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
